2.42
  Price6.61%   +0.1500
(After Hours: 2.40 -0.0200 -0.83%)

Ocugen Inc (OCGN) Stock Discussions on Social Media

- OCGN Stock on Twitter: https://twitter.com/search?q=$ocgn
- OCGN Stock on Reddit: https://www.reddit.com/search/?q=$ocgn
- OCGN Stock on SeekingAlpha: https://seekingalpha.com/symbol/OCGN
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.
Cap:    |  Volume (24h):